Trials / Completed
CompletedNCT04388397
Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients
Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients: A Randomized Clinical Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 477 (actual)
- Sponsor
- Egyptian Biomedical Research Network · Network
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
Detailed description
The study aimed to evaluate and compare patency rate and complications of standard arteriovenous grafts (SAVGs) and immediate-access arteriovenous grafts (IAAVGs) in end stage renal disease (ESRD) patients for one year after the intervention. Patients were randomly divided into two groups: SAVGs group and IAAVGs group. Patients with ESRD with no chance for native AVF were examined clinically and by duplex ultrasonography preoperatively. Follow up was for one year. Primary end points were the success rate, complications rate (hematoma, pseudo-aneurysm, graft site infection, systemic bacteremia), time of first cannulation. Secondary end points were primary and secondary patency within one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Arteriovenous Grafts | Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters. |
Timeline
- Start date
- 2017-08-15
- Primary completion
- 2020-04-10
- Completion
- 2020-04-10
- First posted
- 2020-05-14
- Last updated
- 2020-07-23
Locations
2 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04388397. Inclusion in this directory is not an endorsement.